Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway?

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• The mechanistic target of rapamycin (mTOR) pathway regulates fundamental cellular processes including growth, proliferation, and metabolism.
• Dysregulation of the mTOR pathway is associated with the development and progression of various cancers, notably hepatocellular carcinoma (HCC).

Purpose of the Study:

• To review recent advancements in understanding the mTOR pathway's role in hepatocellular carcinoma.
• To highlight the therapeutic potential of targeting the mTOR pathway in HCC treatment.
• To examine ongoing and completed clinical trials investigating mTOR-targeted therapies for HCC.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of preclinical and clinical data on mTOR pathway inhibitors in HCC.
• Synthesis of information on the mTOR pathway's molecular mechanisms and clinical implications.

Main Results:

• The mTOR pathway is a key regulator of cell growth and survival, and its aberrant activation is common in HCC.
• Targeting the mTOR pathway shows promise as a therapeutic strategy for HCC, with several inhibitors currently in clinical development or use.
• Clinical trials have demonstrated varying degrees of efficacy and toxicity for mTOR inhibitors in HCC patients.

Conclusions:

• The mTOR pathway represents a significant therapeutic target for hepatocellular carcinoma.
• Further research and rational clinical trial design are needed to optimize mTOR-targeted therapies for HCC and other malignancies.
• Understanding the intricate role of mTOR signaling is essential for developing effective cancer treatments.